Bezafibrate–mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats

Abe, 2004, Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis, Pediatr. Int., 46, 597, 10.1111/j.1442-200x.2004.01936.x

Abshagen, 1979, Disposition pharmacokinetics of bezafibrate in man, Eur. J. Clin. Pharmacol., 16, 31, 10.1007/BF00644963

Abshagen, 1980, Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure, Klin. Wochenschr., 58, 889, 10.1007/BF01477001

Agrawal, 1998, Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats, Nephrol. Dial. Transplant., 13, 333, 10.1093/oxfordjournals.ndt.a027827

Akiyama, 1982, Clinical experience in the use of and a pharmacokinetic study of bredinin in renal transplantation, Jpn. J. Transplant., 17, 753

Alsheikh-Ali, 2004, Risk of adverse events with fibrates, Am. J. Cardiol., 94, 935, 10.1016/j.amjcard.2004.06.033

Asavapanumas, 2012, Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways, Drug Metab. Pharmacokinet., 27, 513, 10.2133/dmpk.DMPK-11-RG-123

Burckhardt, 2012, Drug transport by organic anion transporters (OATs), Pharmacol. Ther., 136, 106, 10.1016/j.pharmthera.2012.07.010

Burckhardt, 2003

Burckhardt, 2011, 29

Hilendorf, 2007, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines, Drug Metab. Dispos. Biol. Fate Chem, 35, 1333, 10.1124/dmd.107.014902

Chen, 2014, Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice, Pharm. Res., 32, 538, 10.1007/s11095-014-1483-3

Cho, 2001, The efficacy and safety of mizoribine in living donor kidney transplantation: a 24-week, open-label, prospective study (phase III clinical trial), 3256

Chu, 2012, Species differences in drug transporters and implications for translating preclinical findings to humans, Expert Opin. Drug Metab. Toxicol., 9, 237, 10.1517/17425255.2013.741589

Cundy, 1995, Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother., 39, 1247, 10.1128/AAC.39.6.1247

Endres, 2006, The role of transporters in drug interactions, Eur. J. Pharm. Sci., 27, 501, 10.1016/j.ejps.2005.11.002

Eraly, 2003, Organic anion and cation transporters occur in pairs of similar and similarly expressed genes, Biochem. Biophys. Res. Commun., 300, 333, 10.1016/S0006-291X(02)02853-X

Evans, 1996, Membrane transport as a determinant of the hepatic elimination of drugs and metabolites, Clin. Exp. Pharmacol. Physiol., 23, 970, 10.1111/j.1440-1681.1996.tb01151.x

Feely, 2009

Haubenstock, 1984, Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis, Clin. Chem., 30, 1587, 10.1093/clinchem/30.9.1587

Heidemann, 1981, Rhabdomyolysis with acute renal failure due to bezafibrate, Klin. Wochenschr., 59, 413

Honda, 2006, Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers, Biol. Pharm. Bull., 29, 2460, 10.1248/bpb.29.2460

Huo, 2014, Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats, J. Pharm. Sci., 103, 719, 10.1002/jps.23805

Jappar, 2009, Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters, Pharm. Res., 26, 172, 10.1007/s11095-008-9726-9

Kanterewicz, 1992, Bezafibrate induced rhabdomyolysis, Ann. Rheum. Dis., 51, 536, 10.1136/ard.51.4.536

Khan, 2009, Rhabdomyolysis: a review of the literature, Neth. J. Med., 67, 272

Kittayaruksakul, 2012, Liver X receptor activation downregulates organic anion transporter 1 (OAT1) in the renal proximal tubule, Am. J. Physiol. Renal Physiol., 302, F552, 10.1152/ajprenal.00341.2011

Lee, 2004, Transporters and renal drug elimination, Annu. Rev. Pharmacol., 44, 137, 10.1146/annurev.pharmtox.44.101802.121856

Lerma, 2013

Liu, 2012, Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats, Toxicol. Appl. Pharmacol., 264, 423, 10.1016/j.taap.2012.08.019

Liu, 2014, MDR1 and OAT1/OAT3 mediate the drug–drug interaction between puerarin and methotrexate, Pharm. Res., 31, 1120, 10.1007/s11095-013-1235-9

Maeda, 2014, Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans, Eur. J. Pharm. Sci., 59, 94, 10.1016/j.ejps.2014.04.004

Maki, 2002, Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions, J. Pharmacol. Exp. Ther., 300, 746, 10.1124/jpet.300.3.746

Miller, 1998, Clinical pharmacokinetics of fibric acid derivatives (fibrates), Clin. Pharmacokinet., 34, 155, 10.2165/00003088-199834020-00003

Miyazaki, 2004, The multispecific organic anion transporter family: properties and pharmacological significance, Trends Pharmacol. Sci., 25, 654, 10.1016/j.tips.2004.10.006

Mizuno, 1974, Studies on bredinin. I. Isolation, characterization and biological properties, J. Antibiot., 27, 775, 10.7164/antibiotics.27.775

Monk, 1987, Bezafibrate, Drugs, 33, 539, 10.2165/00003495-198733060-00002

Mori, 2008, Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats, Eur. J. Pharmacol., 586, 52, 10.1016/j.ejphar.2008.02.043

Morimoto, 2005, Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment, Am. J. Med. Sci., 329, 211, 10.1097/00000441-200504000-00009

Motohashi, 2002, Gene expression levels and immunolocalization of organic ion transporters in the human kidney, J. Am. Soc. Nephrol., 13, 866, 10.1681/ASN.V134866

Munns, 2009

Nozaki, 2007, Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices, J. Pharmacol. Exp. Ther., 321, 362, 10.1124/jpet.106.113076

Rizwan, 2007, Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles, Pharm. Res., 24, 450, 10.1007/s11095-006-9181-4

Robertson, 2006, Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion, Pharmacol. Ther. J. Int. Encycl. Pharmacol. Ther., 109, 399

Rumpf, 1984, Bezafibrat-induzierte Myolyse und Myoglobinurie bei Patienten mit eingeschränkter Nierenfunktion, Klin. Wochenschr., 62, 346, 10.1007/BF01716252

Shibasaki, 2004, A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey), Clin. Exp. Nephrol., 8, 117, 10.1007/s10157-004-0276-0

Shitara, 2004, J. Pharmacol. Exp. Ther., 311, 228, 10.1124/jpet.104.068536

Soodvilai, 2004, Acute regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules, Am. J. Physiol. Renal Physiol., 287, F1021, 10.1152/ajprenal.00080.2004

Sugawara, 2005, Structure–affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites, Biochim. Biophys. Acta Biomembr., 1714, 85, 10.1016/j.bbamem.2005.06.006

Takada, 1983, Pharmacokinetics of bredinin in renal transplant patients, Eur. J. Clin. Pharmacol., 24, 457, 10.1007/BF00609886

Takeda, 2001, Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters, Eur. J. Pharmacol., 419, 113, 10.1016/S0014-2999(01)00962-1

Takei, 2002, Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, Pediatr. Int., 44, 205, 10.1046/j.1328-8067.2002.01535.x

Toyoshima, 2013, Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203, J. Pharm. Sci., 102, 3228, 10.1002/jps.23601

Turka, 1991, Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine, J. Clin. Investig., 87, 940, 10.1172/JCI115101

Utsunomiya, 2010, Effects of probenecid on the pharmacokinetics of mizoribine and co-administration of the two drugs in patients with nephrotic syndrome, Int. J. Clin. Pharmacol. Ther., 48, 751, 10.5414/CPP48751

van Roon, 2009, An evidence-based assessment of the clinical significance of drug–drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists, Clin. Ther., 31, 1737, 10.1016/j.clinthera.2009.08.009

Venzano, 1990, A case of acute rhabdomyolysis and acute renal insufficiency caused by the simultaneous use of furosemide and bezafibrate, Minerva Med., 81, 909

Wang, 2014, PEPT1-and OAT1/3-mediated drug–drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human, Eur. J. Pharm. Sci., 63, 77, 10.1016/j.ejps.2014.06.019

Watanabe, 2009, Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments, Drug Metab. Dispos., 37, 1471, 10.1124/dmd.108.026062

Wright, 2004, Molecular and cellular physiology of renal organic cation and anion transport, Physiol. Rev., 84, 987, 10.1152/physrev.00040.2003

Xu, 2013, OAT1 and OAT3: Targets of drug–drug interaction between entecavir and JBP485, Eur. J. Pharm. Sci., 48, 650, 10.1016/j.ejps.2012.12.024

Yamazaki, 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2-and P-glycoprotein-mediated transport, Xenobiotica, 35, 737, 10.1080/00498250500136676

Yatsuga, 2012, Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice, Hum. Mol. Genet., 21, 526, 10.1093/hmg/ddr482

Yeshurun, 1989, Acute severe myositis due to bezafibrate treatment, Harefuah, 116, 261

You, 2004, (Section A: molecular, structural, and cellular biology of drug transporters) The role of organic ion transporters in drug disposition: an update, Curr. Drug Metab., 5, 55, 10.2174/1389200043489207

Zhang, 2010, Pharmacokinetic interaction between JBP485 and cephalexin in rats, Drug Metab. Dispos., 38, 930, 10.1124/dmd.110.032060

Zhu, 2012, Organic anion transporters involved in the excretion of bestatin in the kidney, Peptides, 33, 265, 10.1016/j.peptides.2012.01.007